The US Food and Drug Administration (USFDA) has accepted a New Drug Application (NDA) for Wockhardt Ltd.’s novel antibiotic, Zaynich, marking the first-ever NDA acceptance for a new chemical entity (NCE) from an Indian pharmaceutical company. This milestone is a significant credibility marker for the Mumbai-based drugmaker and a rare innovation story for the Indian pharma sector.
Chairman Habil Khorakiwala told Moneycontrol that the NDA's acceptance—granted only when an application is deemed "proper and full"—validates the company’s scientific data and documentation quality.
Road to Approval and Commercial Launch
Wockhardt is targeting US approval for Zaynich by mid-2026, anticipating a review period of “six to eight months.” Khorakiwala expressed confidence in a positive outcome.
The approval process will include rigorous on-site evaluations by the USFDA, covering manufacturing facilities, documentation, and process checks. Zaynich is produced at USFDA-compliant facilities in Europe, which the company believes will facilitate this phase.
Commercial preparations are already underway. “We have started commercialisation work and are considering several options,” said Khorakiwala, ranging from launching independently to partnering with marketing and distribution firms in the US. The company has also applied for approval in India and plans launches in Europe and other emerging markets in the second half of FY26.
Zaynich: A Novel Weapon Against Superbugs
Zaynich is an innovative antibiotic designed to treat severe, multidrug-resistant “superbug” infections. In global Phase III trials, it demonstrated a 20% higher cure rate compared to Meropenem, a widely used carbapenem antibiotic for serious bacterial infections.
The development of Zaynich culminates Wockhardt’s 25-year research pursuit in novel antibiotics. The company invests approximately ₹200 crore annually in R&D and employs 145 scientists, including 50 PhDs, underscoring its long-term commitment to anti-infective research.
Substantial Market Potential
If approved, Zaynich’s revenue opportunity is substantial. Wockhardt estimates an addressable global patient pool of approximately 2 million in select markets, with a potential $7 billion opportunity in the US and Europe targeting roughly 371,000 carbapenem-resistant cases. China represents another 657,000 potential patients.
In the domestic market, the company estimates around 1.1 million cases could translate into potential annual revenue of ₹17,000 crore. This combined global and domestic potential positions Zaynich as a potential game-changer for Wockhardt’s financial future.